414910-13-7

Basic information

• Product Name: Benzeneacetic acid, α-hydroxy-, (αS)-(2R)-coMpd. with 2-(4-fluoro-2-Methylphenyl)-4-piperidinone (1:1)
• Synonyms: Benzeneacetic acid, α-hydroxy-, (αS)-(2R)-coMpd. with 2-(4-fluoro-2-Methylphenyl)-4-piperidinone (1:1)
• CAS NO: 414910-13-7
• Molecular Formula: C₈H₈O₃*C₁₂H₁₄FNO
• EINECS: -0
• Mol File: 414910-13-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetic acid, α-hydroxy-, (αS)-(2R)-coMpd. with 2-(4-fluoro-2-Methylphenyl)-4-piperidinone (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, α-hydroxy-, (αS)-(2R)-coMpd. with 2-(4-fluoro-2-Methylphenyl)-4-piperidinone (1:1)(414910-13-7)
• EPA Substance Registry System: Benzeneacetic acid, α-hydroxy-, (αS)-(2R)-coMpd. with 2-(4-fluoro-2-Methylphenyl)-4-piperidinone (1:1)(414910-13-7)

Safety Data

• Hazardous Substances Data: 414910-13-7(Hazardous Substances Data)

Upstream product

• 452-63-1 2-Bromo-5-fluorotoluene 
• 579475-69-7 2-(4-fluoro-2-methylphenyl)-4-piperidinone camphor-10-sulfonate 
• 17199-29-0 (S)-Mandelic acid 
• 414909-98-1 phenylmethyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate 
• 620-08-6 4-methoxypyridine 

Downstream Products

• 414910-12-6 (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone 
• 414910-03-5 (2R)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-oxo-1-piperidinecarboxamide 
• 578711-00-9 C₂₅H₂₈F₇N₃O 
• 578710-98-2 C₂₅H₂₈F₇N₃O 
• 578710-96-0 C₂₆H₃₀F₇N₃O 
• 578710-94-8 C₂₆H₃₀F₇N₃O 
• 1265854-91-8 C₂₆H₂₈F₇N₃O 
• 414910-14-8 (2R)-N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-oxo-1-piperidinecarboxamide 

Relevant articles and documents

Discovery and biological characterization of (2 R,4 S)-1′-Acetyl- N -{(1 R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)- N -methyl-4,4′-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) recepto

A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the